Latest News & Insights
Stay Up to Date with Our Community
Featured
Phase 2 trial to evaluate SUN-627, a potent, highly-selective, brain-penetrant, oral allosteric TYK2 inhibitor, in people with progressive forms of...
Phase 2 trial to evaluate SUN-627, a potent, highly-selective, brain-penetrant, oral...
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing...
Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in...
Electra Therapeutics, Inc. today announced the pricing of its upsized initial...
Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing...
$2.5 million grant supports clinical trial activation and patient screening efforts...
Targeting clinically validated pathways to enable patients to achieve freedom from...
Recludix today announced preclinical data for REX-8756, an oral, potent and...
Star Therapeutics to receive $1.25 billion upfront, with up to $750...